Statistically significant changes were observed in candidate biomarkers which are consistent with the vascular activity of BNC105. These include changes in MIP-1beta (p=0.0023), IL-8 (p=0.0007), IL-10 (p-0.0018), TNFR2 (p=0.0001) and IL-16 (p=0.0037). In addition mesothelin levels, a potential marker for mesothelioma, in the patient showing an objective response achieved a decrease to less than 75 percent of baseline after one treatment cycle.

Two additional patients with stable disease similarly achieved decrease in mesothelin to less than 75 percent of baseline. The objective tumour response, safety profile and tolerability of BNC105 warrant further research into its integration with established chemotherapy regimens.